Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. Home/
    2. Media Center/
    3. Press releases /
    4. Innovative Medicine

    Innovative Medicine

    Innovative Medicine
    November 30, 2017

    Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine

    Learn more
    Innovative Medicine
    November 21, 2017

    Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection

    Provides New Treatment Option for Stable, Virologically Suppressed Adults Living with HIV-1
    Learn more
    Innovative Medicine
    November 21, 2017

    Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible

    Learn more
    Innovative Medicine
    November 17, 2017

    New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines

    Learn more
    Innovative Medicine
    November 14, 2017

    INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

    Learn more
    Innovative Medicine
    November 7, 2017

    NEW PHASE 2 DATA SHOW TREATMENT WITH TREMFYA® (GUSELKUMAB) IMPROVED PSORIATIC ARTHRITIS SYMPTOMS THROUGH ONE YEAR

    Longer-Term Results Demonstrate Continued Efficacy of Anti-Interleukin 23 Monoclonal Antibody TREMFYA® in Improving Joint and Skin Symptoms Associated with Active Psoriatic Arthritis
    Learn more
    Innovative Medicine
    November 6, 2017

    STELARA® (USTEKINUMAB) SHOWS POSITIVE RESULTS IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PHASE 2 TRIAL

    Learn more
    Innovative Medicine
    November 3, 2017

    INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease

    Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting
    Learn more
    Innovative Medicine
    November 1, 2017

    ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio

    Learn more
    Load more